399 related articles for article (PubMed ID: 17610348)
1. Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome.
Bulcão C; Ribeiro-Filho FF; Sañudo A; Roberta Ferreira SG
Am J Cardiovasc Drugs; 2007; 7(3):219-24. PubMed ID: 17610348
[TBL] [Abstract][Full Text] [Related]
2. Are the beneficial cardiovascular effects of simvastatin and metformin also associated with a hormone-dependent mechanism improving insulin sensitivity?
Bulcão C; Giuffrida FM; Ribeiro-Filho FF; Ferreira SR
Braz J Med Biol Res; 2007 Feb; 40(2):229-35. PubMed ID: 17273659
[TBL] [Abstract][Full Text] [Related]
3. Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients.
Bays HE; Stein EA; Shah AK; Maccubbin DL; Mitchel YB; Mercuri M
Am J Cardiol; 2002 Nov; 90(9):942-6. PubMed ID: 12398959
[TBL] [Abstract][Full Text] [Related]
4. Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe.
Kater AL; Batista MC; Ferreira SR
Metabolism; 2010 Jun; 59(6):921-6. PubMed ID: 20199786
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance.
Moutzouri E; Liberopoulos E; Mikhailidis DP; Kostapanos MS; Kei AA; Milionis H; Elisaf M
Int J Clin Pract; 2011 Nov; 65(11):1141-8. PubMed ID: 21995692
[TBL] [Abstract][Full Text] [Related]
6. Lymphocyte-suppressing and systemic anti-inflammatory effects of high-dose metformin in simvastatin-treated patients with impaired fasting glucose.
Krysiak R; Okopien B
Atherosclerosis; 2012 Dec; 225(2):403-7. PubMed ID: 23107042
[TBL] [Abstract][Full Text] [Related]
7. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
[TBL] [Abstract][Full Text] [Related]
8. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
[TBL] [Abstract][Full Text] [Related]
10. Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies.
Karakas SE; Banaszewska B; Spaczynski RZ; Pawelczyk L; Duleba A
Gynecol Endocrinol; 2013 May; 29(5):483-7. PubMed ID: 23480783
[TBL] [Abstract][Full Text] [Related]
11. Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes.
Bellia A; Rizza S; Galli A; Fabiano R; Donadel G; Lombardo MF; Cardillo C; Sbraccia P; Tesauro M; Lauro D
Atherosclerosis; 2010 May; 210(1):199-201. PubMed ID: 20018286
[TBL] [Abstract][Full Text] [Related]
12. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients.
Panichi V; Paoletti S; Mantuano E; Manca-Rizza G; Filippi C; Santi S; Taccola D; Donadio C; Tramonti G; Innocenti M; Casto G; Consani C; Sbragia G; Franzoni F; Galetta F; Panicucci E; Barsotti G
Nephrol Dial Transplant; 2006 Feb; 21(2):337-44. PubMed ID: 16249194
[TBL] [Abstract][Full Text] [Related]
13. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
Bayés B; Granada ML; Lauzurica R; Pastor MC; Navarro M; Bonet J; Llopis MA; Romero R
Transplant Proc; 2005 Nov; 37(9):3808-12. PubMed ID: 16386546
[TBL] [Abstract][Full Text] [Related]
14. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
[TBL] [Abstract][Full Text] [Related]
15. Identical LDL-cholesterol lowering but non-identical effects on NF-κB activity: High dose simvastatin vs combination therapy with ezetimibe.
Rudofsky G; Reismann P; Groener JB; Djuric Z; Fleming T; Metzner C; Grafe IA; Bierhaus A; Nawroth PP
Atherosclerosis; 2012 Jul; 223(1):190-6. PubMed ID: 22633472
[TBL] [Abstract][Full Text] [Related]
16. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
[TBL] [Abstract][Full Text] [Related]
17. Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients.
Szendroedi J; Anderwald C; Krssak M; Bayerle-Eder M; Esterbauer H; Pfeiler G; Brehm A; Nowotny P; Hofer A; Waldhäusl W; Roden M
Diabetes Care; 2009 Feb; 32(2):209-14. PubMed ID: 18957532
[TBL] [Abstract][Full Text] [Related]
18. An investigation into the therapeutic effects of statins with metformin on polycystic ovary syndrome: a meta-analysis of randomised controlled trials.
Sun J; Yuan Y; Cai R; Sun H; Zhou Y; Wang P; Huang R; Xia W; Wang S
BMJ Open; 2015 Mar; 5(3):e007280. PubMed ID: 25818277
[TBL] [Abstract][Full Text] [Related]
19. The effect of short-term simvastatin treatment on plasma adipokine levels in patients with isolated hypercholesterolemia: A preliminary report.
Krysiak R; Zmuda W; Okopień B
Pharmacol Rep; 2014 Oct; 66(5):880-4. PubMed ID: 25149995
[TBL] [Abstract][Full Text] [Related]
20. Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk.
Rosen JB; Ballantyne CM; Hsueh WA; Lin J; Shah AK; Lowe RS; Tershakovec AM
Lipids Health Dis; 2015 Sep; 14():103. PubMed ID: 26336957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
